Trial · NCT07889284
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
NCT07889284, Phase 3, Not yet recruiting, ScandiBio Therapeutics AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout. Trials, record NCT07889284. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889284
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
- NCT number
- NCT07889284
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 336 participants, estimated
- Lead sponsor
- ScandiBio Therapeutics AB
- Conditions
- Gout Disease
- Interventions
- Combined metabolic activators, Collagen and maltodextrin
- First posted
- 2026-10-22
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo. | 4 weeks | Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks). |
| Secondary | To evaluate the effect of 4 weeks of CMA2 treatment on patient global assessment (PGA, 100 mm) compared with placebo. | 4 weeks | Change in Patient Global Assessment (PGA, 100 mm) score from baseline to end-of-treatment. PGA is assessed using a visual analogue scale (VAS) ranging from 0 to 10 or 0 to 100, where higher scores indicate worse disease activity. |
| Secondary | To evaluate the effect of 4 weeks of CMA2 treatment on High Sensitivity C-reactive Protein (hsCRP) levels compared with placebo. | 4 weeks | Percentage change in High Sensitivity C-reactive Protein (hsCRP) levels from baseline to end-of-treatment. |
| Secondary | To evaluate the proportion of participants achieving serum uric acid levels < 6 mg/dL. | 4 weeks | Proportion of patients with a serum uric acid level \<6 .0 mg/dL at end-of-treatment. |
| Secondary | To evaluate the effect of 2-weeks administration of CMA2 treatment on serum uric acid levels compared with placebo. | 2 weeks | Change in serum uric acid levels from baseline to 2-weeks. |
| Secondary | To evaluate patient adherence to the twice-daily treatment regimen. | 4 weeks | Percentage of expected twice-daily study drug doses successfully administered, as assessed by sachet counts. |
| Secondary | To evaluate the incidence of adverse events (AEs). | 6 weeks | The percentage of subjects experiencing at least one AE during the study period. |
| Secondary | To evaluate the severity of AEs. | 6 weeks | The incidence of AEs categorized by maximum severity grade. |
| Secondary | To evaluate the incidence of serious adverse events (SAEs). | 6 weeks | The percentage of subjects experiencing at least one SAE during the study period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889284
GET https://conductscience.org/api/trials/v1/NCT07889284/registered